Nexalin Technology, Inc. (NASDAQ:NXL – Get Free Report) was the target of a large decline in short interest in March. As of March 13th, there was short interest totaling 440,670 shares, a decline of 26.4% from the February 26th total of 598,666 shares. Approximately 3.2% of the company’s stock are short sold. Based on an average trading volume of 108,359 shares, the days-to-cover ratio is presently 4.1 days.
Analyst Ratings Changes
Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nexalin Technology in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Nexalin Technology has a consensus rating of “Sell”.
Check Out Our Latest Stock Analysis on NXL
Institutional Investors Weigh In On Nexalin Technology
Nexalin Technology Price Performance
Shares of NXL traded down $0.01 during mid-day trading on Friday, hitting $0.36. 48,955 shares of the company’s stock were exchanged, compared to its average volume of 131,598. Nexalin Technology has a 52 week low of $0.36 and a 52 week high of $2.31. The company has a market cap of $7.50 million, a PE ratio of -0.71 and a beta of 4.05. The company has a 50-day simple moving average of $0.49 and a 200 day simple moving average of $0.84.
Nexalin Technology (NASDAQ:NXL – Get Free Report) last announced its quarterly earnings data on Wednesday, March 25th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). Nexalin Technology had a negative return on equity of 0.87% and a negative net margin of 2,722.19%.The business had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.08 million.
About Nexalin Technology
Nexalin Technology, Inc is a U.S.-based medical device company specializing in noninvasive neuromodulation therapies for mental health conditions. The company develops and markets the Nexalin® medical device platform, which delivers proprietary alternating current waveforms to targeted areas of the brain through forehead-mounted electrodes. Its technology is designed to modulate neural activity without pharmaceuticals, positioning the company within the growing field of digital therapeutics and neurostimulation.
The Nexalin device has received U.S.
Featured Stories
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.
